Cart
Research Literature Overview

GLP-1/GIP/Glucagon Triple Agonists: A Metabolic Research Overview

Published August 2, 2026 · ROVIQ Research

Triple receptor agonists — compounds designed to simultaneously activate the GLP-1, GIP, and glucagon receptors — represent the newest generation of incretin-pathway research, following single-receptor (GLP-1-only) and dual-receptor (GIP/GLP-1) agonists. This overview covers the mechanistic rationale for triple agonism and summarizes what has been published in the peer-reviewed literature, including preclinical research and published human clinical trial data.

Mechanism: Three Receptors, Three Roles

GLP-1 and GIP are both incretin hormones that stimulate insulin secretion from pancreatic β-cells, but they diverge in other effects: GIP has a glucagonotropic effect during hypoglycemia, while GLP-1 is glucagonostatic during hyperglycemia. GIP also assists GLP-1 in central and peripheral pathways affecting lipolysis and fat oxidation (Liu, 2024).

Glucagon receptor activation is the mechanistic feature that distinguishes a triple agonist from a dual GIP/GLP-1 agonist: it increases energy expenditure by stimulating glucose production, fat oxidation, and mobilization of energy stores. A 2022 preclinical study in diet-induced obese mice found that optimized triple agonists normalized body weight and enhanced energy expenditure more than GLP-1 mono-agonists or GLP-1/GIP dual agonists, attributing the difference specifically to glucagon receptor engagement (Knerr et al., 2022).

Published Human Trial Data

Retatrutide, a GLP-1/GIP/glucagon triple agonist, has been studied in published, peer-reviewed randomized controlled trials. A Phase 2 trial in 338 adults with obesity, published in the New England Journal of Medicine, reported dose-dependent body weight reduction over 48 weeks, with gastrointestinal effects (nausea, vomiting, diarrhea) as the most common adverse events — consistent with the broader GLP-1 receptor agonist drug class (Jastreboff et al., 2023).

A separate Phase 2a trial in 98 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) measured liver fat directly via imaging, reporting dose-dependent relative liver fat reduction ranging from -42.9% (1 mg) to -82.4% (12 mg) at 24 weeks, versus +0.3% in the placebo group (Sanyal et al., 2024).

Important distinction: the trials cited above were conducted by the pharmaceutical developer of retatrutide, using a specific investigational drug formulation, dosing protocol, and clinical oversight, as part of a regulated drug development program. They are cited here as published research on the receptor mechanism — they are not a description, endorsement, or prediction of outcomes for any product sold by ROVIQ. ROVIQ's compounds are sold exclusively for laboratory research use and have not themselves been through this or any clinical trial process.

References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
  2. Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. PMID: 35809773
  3. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024. PMID: 39114288
  4. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523
This article is for laboratory research reference only. It summarizes published mechanism-of-action and clinical trial literature on a receptor pharmacology class — it does not describe, promote, or make claims about any product sold by ROVIQ. ROVIQ's compounds are intended strictly for research and laboratory use — not for human or animal consumption. Nothing here constitutes dosing, medical, or health guidance.
View ROVIQ's GLP-3 Research Compounds →